Shares of Cumberland Pharmaceuticals Inc. (CPIX) are up over 20% in premarket hours today, following positive top-line results from its Phase 2 FIGHT DMD trial.
The FIGHT DMD trial is a phase II study evaluating Ifetroban, a novel oral therapy, targeting cardiac complications in Duchenne muscular dystrophy or DMD patients. The primary endpoint of the trial was an improvement in the heart's left ventricular ejection fractions.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.